Effect of the structural modification of Candesartan with Zinc on hypertension and left ventricular hypertrophy

Martínez, Valeria R.; Lima, Augusto Martins; Stergiopulos, Nikolaous; Rueda, Jorge Omar Vélez; Islas, María Soledad; Griera, Mercedes; Calleros, Laura; Puyol, Manuel Rodríguez; Giusti, C; Portiansky, Enrique Leo; Ferrer, Evelina G.; Giusti, Verónica Celeste De; Williams, Patricia A. M.

doi:10.1016/j.ejphar.2023.175654

Cited by 6 publications

(1 citation statement)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, research has shown that the cardioprotective effects of ARB antihypertensive drugs, such as candesartan, are partly independent of blood pressure ( 43 ). ZnCand, a coordination complex synthesized between the ARB candesartan and Zn(II), can exert cardioprotective effects by suppressing NOX2 to inhibit oxidative stress and restore redox homeostasis ( 44 ). Losartan regulates macrophage polarization via the TLR4/NF-κB/MAPK pathway to alleviate sepsis-induced myocardial injury ( 45 ).…”

Section: Discussionmentioning

confidence: 99%

Transcriptome and proteome analyses reveal that upregulation of GSTM2 by allisartan improves cardiac remodeling and dysfunction in hypertensive rats

Wu,

Zhai,

et al. 2024

Exp Ther Med

View full text Add to dashboard Cite

Long-term hypertension can lead to hypertensive heart disease, which ultimately progresses to heart failure. As an angiotensin receptor blocker antihypertensive drug, allisartan can control blood pressure, and improve cardiac remodeling and cardiac dysfunction caused by hypertension. The aim of the present study was to investigate the protective effects of allisartan on the heart of spontaneously hypertensive rats (SHRs) and the underlying mechanisms. SHRs were used as an animal model of hypertensive heart disease and were treated with allisartan orally at a dose of 25 mg/kg/day. The blood pressure levels of the rats were continuously monitored, their body and heart weights were measured, and their cardiac structure and function were evaluated using echocardiography. Wheat germ agglutinin staining and Masson trichrome staining were employed to assess the morphology of the myocardial tissue. In addition, transcriptome and proteome analyses were performed using the Solexa/Illumina sequencing platform and tandem mass tag technology, respectively. Immunofluorescence co-localization was conducted to analyze Nrf2 nuclear translocation, and TUNEL was performed to detect the levels of cell apoptosis. The protein expression levels of pro-collagen I, collagen III, phosphorylated (p)-AKT, AKT, p-PI3K and PI3K, and the mRNA expression levels of Col1a1 and Col3a1 were determined by western blotting and reverse transcription-quantitative PCR, respectively. Allisartan lowered blood pressure, attenuated cardiac remodeling and improved cardiac function in SHRs. In addition, allisartan alleviated cardiomyocyte hypertrophy and cardiac fibrosis. Allisartan also significantly affected the ‘pentose phosphate pathway’, ‘fatty acid elongation’, ‘valine, leucine and isoleucine degradation’, ‘glutathione metabolism’, and ‘amino sugar and nucleotide sugar metabolism’ pathways in the hearts of SHRs, and upregulated the expression levels of GSTM2. Furthermore, allisartan activated the PI3K-AKT-Nrf2 signaling pathway and inhibited cardiomyocyte apoptosis. In conclusion, the present study demonstrated that allisartan can effectively control blood pressure in SHRs, and improves cardiac remodeling and cardiac dysfunction. Allisartan may also upregulate the expression levels of GSTM2 in the hearts of SHRs and significantly affect glutathione metabolism, as determined by transcriptome and proteome analyses. The cardioprotective effect of allisartan may be mediated through activation of the PI3K-AKT-Nrf2 signaling pathway, upregulation of GSTM2 expression and reduction of cardiomyocyte apoptosis in SHRs.

show abstract

Section: Discussionmentioning

confidence: 99%